Key Patents Wiped Out For Acorda's Flagship MS Drug
A Delaware federal judge on Friday nixed four patents shielding Acorda Therapeutics' multiple sclerosis drug Ampyra, paving the way for generics to hit the market nearly 10 years earlier than expected...To view the full article, register now.
Already a subscriber? Click here to view full article